基因型耐药指导治疗与经验性治疗对难治性幽门螺杆菌感染的疗效比较
两项多中心开放标签随机对照试验纳入既往至少2次治疗失败的幽门螺杆菌感染患者,比较基因型耐药指导治疗与依据用药史的经验性治疗14天的根除率。试验1中两组根除率分别为81%与60%,试验2中分别为78%与72.2%,组间差异均无统计学意义;不良反应与依从性无显著差异。
要点
- 难治性幽门螺杆菌感染中,基因型耐药指导治疗与经验性治疗的根除率无显著差异。
- 试验1因多西环素序贯治疗根除率低(57.7%)提前终止。
- 两组不良反应频率与依从性无显著差异。
核心结论
- 精心设计的、基于用药史的经验性治疗可作为基因型耐药指导治疗的替代选择,用于根除难治性幽门螺杆菌感染,但需考虑可及性、成本和患者偏好。
研究设计与样本
- 两项多中心、开放标签随机对照试验,纳入2012年10月至2017年9月台湾地区20岁及以上、既往至少2次治疗方案失败的幽门螺杆菌感染患者。
- 试验1随机分配至基因型耐药指导治疗组(n=21)或经验性治疗组(n=20);试验2两组各n=205。
- 两组均接受14天序贯治疗:前7天埃索美拉唑联合阿莫西林,后7天埃索美拉唑联合甲硝唑,并根据耐药基因标记加用左氧氟沙星、克拉霉素或多西环素(试验1)或四环素(试验2),均每日两次。
- 耐药相关突变通过聚合酶链反应直接测序检测23S核糖体RNA或旋转酶A;根除状态通过13C-尿素呼气试验判定;主要结局为根除率。
主要发现
- 试验1中,基因型耐药指导治疗组根除17/21(81%),经验性治疗组根除12/20(60%),P=0.181。
- 试验1因多西环素序贯治疗患者根除率低(15/26[57.7%])提前终止。
- 试验2意向性分析中,基因型耐药指导治疗组根除160/205(78%),经验性治疗组根除148/205(72.2%),P=0.170。
- 两组不良反应频率与依从性无显著差异。
临床怎么用
- 原文结论认为,基于用药史的经验性治疗可作为基因型耐药指导治疗的替代选择,需考虑可及性、成本和患者偏好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We aimed to compare the efficacy of genotypic resistance-guided therapy vs empirical therapy for eradication of refractory Helicobacter pylori infection in randomized controlled trials. METHODS: We performed 2 multicenter, open-label trials of patients with H pylori infection (20 years or older) failed by 2 or more previous treatment regimens, from October 2012 through September 2017 in Taiwan. The patients were randomly assigned to groups given genotypic resistance-guided therapy for 14 days (n = 21 in trial 1, n = 205 in trial 2) or empirical therapy according to medication history for 14 days (n = 20 in trial 1, n = 205 in trial 2). Patients received sequential therapy containing esomeprazole and amoxicillin for the first 7 days, followed by esomeprazole and metronidazole, with levofloxacin, clarithromycin, or tetracycline (doxycycline in trial 1, tetracycline in trial 2) for another 7 days (all given twice daily) based on genotype markers of resistance determined from gastric biopsy specimens (group A) or empirical therapy according to medication history. Resistance-associated mutations in 23S ribosomal RNA or gyrase A were identified by polymerase chain reaction with direct sequencing. Eradication status was determined by 13C-urea breath test. The primary outcome was eradication rate. RESULTS: H pylori infection was eradicated in 17 of 21 (81%) patients receiving genotype resistance-guided therapy and 12 of 20 (60%) patients receiving empirical therapy (P = .181) in trial 1. This trial was terminated ahead of schedule due to the low rate of eradication in patients given doxycycline sequential therapy (15 of 26 [57.7%]). In trial 2, H pylori infection was eradicated in 160 of 205 (78%) patients receiving genotype resistance-guided therapy and 148 of 205 (72.2%) patients receiving empirical therapy (P = .170), according to intent to treat analysis. The frequencies of adverse effects and compliance did not differ significantly between groups. CONCLUSIONS: Properly designed empirical therapy, based on medication history, is an acceptable alternative to genotypic resistance-guided therapy for eradication of refractory H pylori infection after consideration of accessibility, cost, and patient preference. ClinicalTrials.gov ID: NCT01725906.
引用
- Liou JM, Chen PY, Luo JC, et al. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology. 2018. PMID: 29964036. doi:10.1053/j.gastro.2018.06.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。